Latest Financial Results

Q3 2019

Quarterly Results

Ended Jul 31, 2019

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Anixa is focused on harnessing the body’s immune system in the fight against cancer.  Anixa’s therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease.  Anixa’s diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body’s immune response to the presence of a malignancy.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization. 

Logo Itus

Latest News & Events

Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium

Read More...

Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study

Read More...

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek™ Prostate Cancer Study

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.